natgillin/translations-raw huggingface dataset:
Body weight - Plasma clearance of fondaparinux increases with body weight (9% increase per 10 kg).
Tjelesna težina - klirens iz plazme fondaparinuksa povećava se s povećanjem tjelesne težine (povećanje od 9% na 10 kg).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu.
For additional instructions for use and handling and disposal see section 6.6.
Za dodatne upute za primjenu, rukovanje i odlaganje vidjeti dio 6.6.
• Keep this medicine out of the sight and reach of children
• Ovaj lijek čuvajte izvan pogleda i dohvata djece.
No conclusion can be drawn with regard to clinical efficacy in this uncontrolled study.
Ne mogu se izvoditi zaključci iz ovog nekontroliranog ispitivanja u pogledu kliničke djelotvornosti.
Release the plunger and the needle will automatically withdraw from the skin and go back into the security sleeve where it will be locked permanently (picture F).
Otpustite klip i igla će se automatski izvući iz kože i povući u zaštitni valjak, gdje će biti trajno zatvorena (Slika F).
The incidence of symptomatic VTE, including PE was not significantly different between treatment groups.
Incidencija simptomatskih VTE, uključujući PE nije se značajno razlikovala između skupina.
Treatment should be continued for at least 5 days and until adequate oral anticoagulation is established (International Normalised Ratio 2 to 3).
Liječenje treba nastaviti najmanje 5 dana, te dok se ne uspostavi adekvatno liječenje oralnim antikoagulansima (internacionalni normalizirani omjer (INR) 2 do 3).
This is shown in Picture 3 at the beginning of these instructions
To je prikazano na slici 3 koja se nalazi na početku uputa za primjenu.
Tell your doctor if you are allergic to latex before being treated with Arixtra.
Recite svom liječniku ako ste alergični na lateks gumu prije nego primijenite lijek Arixtra.
There is no known antidote to fondaparinux.
Nema poznatog antidota za fondaparinuks.
• Do not touch the needle or allow it to touch any surface before the injection.
• Ne dodirujte iglu i pazite da igla ne dotakne nikakvu površinu prije injiciranja.
Severe allergic reactions (anaphylaxis): These are very rare in people (up to 1 in 10,000) taking Arixtra.
Teške alergijske reakcije (anafilaksija): One su vrlo rijetke u osoba (manje od 1 na 10 000) koje uzimaju lijek Arixtra.
The injection should not be given unless haemostasis has been established (see section 4.4).
Injekciju se ne smije dati ukoliko nije uspostavljena odgovarajuća hemostaza (vidjeti dio 4.4).
Hold the syringe firmly by the finger grip.
Čvrsto držite štrcaljku za hvatište za prst.
• increase in the amount of non-protein nitrogen in the blood
• porast razine neproteinskog dušika u krvi
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
• Periodička izvješća o neškodljivosti Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107.c stavkom 7. Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
To treat some types of heart attack, a health professional may give the first dose into a vein (intravenously).
U liječenju nekih oblika srčanog udara liječnik prvu dozu može dati u venu (intravenski).
The whole length of the needle should be inserted perpendicularly into a skin fold held between the thumb and the forefinger; the skin fold should be held throughout the injection.
Iglu treba uvesti cijelom dužinom okomito u nabor kože koji se drži između palca i kažiprsta; nabor kože treba držati cijelo vrijeme injiciranja.
Latex Allergy
Alergija na lateks
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER BOX
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA
• fainting or dizziness, low blood pressure
• nesvjestica ili omaglica, niski krvni tlak
There are no data available on the effect of fondaparinux on human fertility.
Nema raspoloživih podataka o učinku fondaparinuksa na plodnost u ljudi.
After the injection hold the syringe in one hand by gripping the security sleeve, use the other hand to hold the finger grip and pull firmly back.
Nakon injiciranja držite štrcaljku u jednoj ruci povlačeći zaštitni valjak, s drugom rukom držite hvatač za prst te čvrsto povucite natrag.
Do not dispose of the used syringe in the household waste.
Upotrijebljenu štrcaljku nemojte baciti u kućni otpad.
Spinal / Epidural anaesthesia
Spinalna/epiduralna anestezija
Animal studies do not show any effect on fertility.
Studije na životinjama ne pokazuju utjecaj na plodnost.
One type of syringe has an automatic needle protection system and the other type has a manual needle protection system.
Jedan tip štrcaljke ima automatski sustav zaštite od igle, a drugi tip ima ručni sustav zaštite od igle.
Rare: post-operative wound infection
Rijetko: postoperativna infekcija rane
Do not throw away any medicines or syringes via wastewater or household waste.
Nikada nemojte nikakve lijekove bacati u otpadne vode ili kućni otpad.
The difference in mortality was statistically significant in stratum 1 (placebo comparator) but not in stratum 2 (UFH comparator).
Razlika u mortalitetu bila je statistički značajna u stratumu 1 (u usporedbi s placebom), ali ne i u stratumu 2 (u usporedbi s nefrakcioniranim heparinom).
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje gotovog lijeka u promet:
Choose a place in the lower abdominal (tummy) area, at least 5 cm below your belly button (picture A).
Izaberite mjesto na donjem dijelu trbuha, najmanje 5 cm ispod pupka (Slika A).
The difference in total VTE rates between the treatment groups, which was not statistically significant, was mainly due to a reduction of asymptomatic distal DVT.
Razlika između skupina u ukupnom broju VTE, koja nije statistički značajna, uglavnom je nastala zbog manjeg broja asimptomatskih distalnih DVT.
Of the patients treated with a thrombolytic, 84% were treated with a non-fibrin specific agent (primarily streptokinase).
Od bolesnika koji su primali trombolitike, 84% ih je liječeno nespecifičnim fibrinolitičkim agensima (prvenstveno streptokinazom).
• If you are not sure what to do, ask your doctor or pharmacist.
• Ako niste sigurni što učiniti, upitajte svog liječnika ili ljekarnika.
You should continue Arixtra treatment for as long as your doctor has told you, since Arixtra prevents development of a serious condition.
Liječenje lijekom Arixtra trebate nastaviti onoliko dugo koliko Vam je preporučio liječnik, jer Arixtra sprječava razvoj ozbiljnih komplikacija.
• Arixtra does not have to be kept in the fridge.
• Lijek Arixtra ne morate čuvati u hladnjaku.
Treatment of Pulmonary Embolism
Liječenje plućne embolije
Arixtra is used to:
Arixtra se koristi:
Elderly patients - No dosing adjustment is necessary.
Stariji bolesnici - nije potrebna prilagodba doziranja.
However, studies performed in Asian (Japanese) healthy subjects did not reveal a different pharmacokinetic profile compared to Caucasian healthy subjects.
Međutim, studija provedena na zdravim osobama u Aziji (Japanci), nije pokazala drugačiji farmakokinetski profil u usporedbi sa zdravim bijelcima.
What Arixtra is and what it is used for
Što je Arixtra i za što se koristi
• Do not inject Arixtra into muscle.
• Nemojte lijek Arixtra ubrizgavati u mišić.
The diagnosis was confirmed by objective testing (lung scan, pulmonary angiography or spiral CT scan).
Dijagnoza je potvrđena objektivnim testovima (sken pluća, angiografija pluća ili spiralni CT).
Therefore the physician should determine if the benefit of treatment outweighs the risk (see sections 4.2 and 4.3).
Stoga liječnik treba odlučiti da li korist od liječenja nadmašuje rizik (vidjeti dio 4.2 i
The majority of endpoint events were diagnosed by a prescheduled venography and consisted mainly of distal DVT, but the incidence of proximal DVT was also significantly reduced.
Većina događaja mjere ishoda dijagnosticirana je prethodno planiranom venografijom i obuhvaćala je uglavnom distalnu DVT, no i incidencija proksimalne DVT je bila značajno smanjena.
These instructions are for both types of syringes (automatic and manual needle protection system).
Ove upute vrijede za oba tipa štrcaljki (s automatskim i ručnim sigurnosnim sustavom za iglu).
Treatment should be continued until the risk of venous thrombo-embolism has diminished, usually until the patient is ambulant, at least 5 to 9 days after surgery.
Liječenje treba nastaviti do smanjenja rizika od venske tromboembolije, obično dok bolesnik ponovno ne postane pokretan, a najmanje 5-9 dana nakon operacije.
The active substance is:
Djelatna tvar je:
• treat some types of heart attack and severe angina (pain caused by narrowing of the arteries in the heart).
• za liječenje nekih oblika srčanog udara i teške angine pektoris (boli uzrokovane suženjem srčanih arterija)
Fondaparinux does not bind significantly to other plasma proteins, including platelet factor 4 (PF4).
Fondaparinuks se ne veže značajno na druge proteine plazme, uključujući trombocitni faktor 4 (PF4).
The risk of these rare events may be higher with postoperative use of indwelling epidural catheters or the concomitant use of other medicinal products affecting haemostasis.
Rizik od nastupa tih rijetkih događaja može se povećati postoperativnom uporabom trajnih epiduralnih katetera ili istodobnom primjenom drugih lijekova koji utječu na hemostazu.
Fondaparinux is administered by deep subcutaneous injection while the patient is lying down.
Fondaparinuks se primjenjuje dubokom supkutanom injekcijom dok bolesnik leži.
If administered via a minibag, the infusion should be given over 1 to 2 minutes.
Ako se primjenjuje mala količina otopine iz vrećice, infuziju treba davati kroz 1-2 minute.
Race - Pharmacokinetic differences due to race have not been studied prospectively.
Rasa - farmakokinetske razlike među rasama nisu prospektivno ispitivane.
What you need to know before you use Arixtra
Što morate znati prije nego počnete primjenjivati lijek Arixtra
If fondaparinux sodium is added to a 0.9% saline minibag it should ideally be infused immediately, but can be stored at room temperature for up to 24 hours.
Ako se fondaparinuksnatrij dodaje u malu vrećicu 0,9 % fiziološke otopine trebalo bi ga primijeniti odmah, ali se može čuvati pri sobnoj temperaturi najdulje do 24 sata.
• wound infection
• infekcija rane
Aspen Notre Dame de Bondeville, 1 rue de l'Abbaye, F-76960 Notre Dame de Bondeville, France.
Aspen Notre Dame de Bondeville, 1 rue de l'Abbaye, F-76960 Notre Dame de Bondeville, Francuska
The mortality benefit shown in the fondaparinux group was maintained until the end of follow-up at Day 180.
Smanjeni mortalitet zabilježen u skupini liječenoj fondaparinuksom održan je do kraja razdoblja praćenja od 180 dana.
Fondaparinux is excreted to 64 - 77 % by the kidney as unchanged compound.
Fondaparinuks se 64 - 77 % izlučuje putem bubrega u neizmijenjenom obliku.
• Arixtra is given by injection under the skin (subcutaneously) into a skin fold of the lower abdominal area.
• Arixtra se daje injekcijom pod kožu (supkutano) u kožni nabor na području donjeg dijela trbuha.
Fondaparinux does not inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4) in vitro.
Fondaparinuks ne inhibira enzime CYP450 (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6,
The baseline characteristics and duration of fondaparinux treatment were comparable in both UFH
Ishodišne karakteristike i trajanje liječenja fondaparinuksom su bile usporedive za obje UFH skupine.
The most common adverse reactions were bleeding complications (see section 4.4).
Najčešće nuspojave bile su komplikacije zbog krvarenja (vidjeti dio 4.4).
Your weight
Vaša tjelesna težina
A similar pattern is observed in DVT and PE treatment patients.
Sličan uzorak je zabilježen u liječenju DVT i PE.
The repeated dose and reproduction toxicity studies did not reveal any special risk but did not provide adequate documentation of safety margins due to limited exposure in the animal species.
Ispitivanja toksičnosti ponovljenih doza i reproduktivne toksičnosti nisu pokazala nikakav posebni rizik, ali zbog ograničene izloženosti ispitivanih životinjskih vrsta ne dokumentiraju dovoljno sigurnosne granice.
Peri-PCI major bleeding or death,
Peri-PCI veliko krvarenje ili smrt,
Two patients had reports of bleeding during the study.
U dva je bolesnika prijavljeno krvarenje tijekom trajanja ispitivanja.
The fondaparinux dose (10 mg) in the interaction studies was higher than the dose recommended for the present indications.
ispitivanjima interakcija doza fondaparinuksa (10 mg) je bila veća od preporučene doze za sadašnje indikacije.
Treatment should be continued for a minimum of 30 days and up to a maximum of 45 days in patients at high risk of thromboembolic complications (see sections 4.4 and 5.1).
Liječenje treba provoditi tijekom minimalno 30 dana do maksimalno 45 dana u bolesnika s visokim rizikom od nastanka tromboembolijskih komplikacija (vidjeti dio 4.4 i 5.1).
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and genotoxicity.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja farmakološke sigurnosti i genotoksičnosti.
Some other medicines may affect the way that Arixtra works or be affected by Arixtra.
Neki drugi lijekovi mogu utjecati na djelovanje lijeka Arixtra ili obrnuto.
Contact your doctor or pharmacist for advice as soon as possible because of the increased risk of bleeding.
Obavijestite svog liječnika ili ljekarnika što je prije moguće zbog povećanog rizika od krvarenja.
The majority of events were asymptomatic distal DVT.
većini slučajeva radilo se o asimptomatskoj DVT.
The mean treatment duration was 6.2 days on fondaparinux.
Prosječno trajanje liječenja iznosilo je 6,2 dana za bolesnike na fondaparinuksu.
The associated 5th and 95th percentiles are, respectively, 0.97 and 1.92 for Cmax (mg/l), and 0.24 and 0.95 for Cmin (mg/l).
Pridružena 5. i 95. percentila je 0,97 i 1,92 za Cmax (mg/l), te 0,24 i 0,95 za Cmin (mg/l).
There are no adequate data from the use of fondaparinux in pregnant women.
Nema adekvatnih podataka o primjeni fondaparinuksa u trudnica.
Aspen Notre Dame de Bondeville 1, rue de l'Abbaye F-76960 Notre Dame de Bondeville France
Aspen Notre Dame de Bondeville 1 rue de l'Abbaye F-76960 Notre Dame de Bondeville Francuska
If injecting in the lower abdominal area is not possible, ask your nurse or doctor for advice.
Ako nije moguća primjena u donji dio trbuha, potražite savjet medicinske sestre ili svog liječnika.
The mean age of the patients was 61 years, and approximately 40% were at least 65 years old.
Prosječna dob bolesnika iznosila je 61 godinu, a otprilike ih je 40% bilo staro najmanje 65 godina.
However, rare spontaneous reports of aPTT prolongation have been received.
Međutim, zaprimljeni su i rijetki, pojedinačni izvještaji o produženju vrijednosti APTV-a.
Fondaparinux does not inactivate thrombin (activated Factor II) and has no effects on platelets.
Fondaparinuks ne inaktivira trombin (aktivirani faktor II) i nema učinka na trombocite.
Paediatric patients - Limited data are available in paediatric patients (see section 5.1).
Pedijatrijska populacija - ograničeni su podaci dostupni za pedijatrijske bolesnike (vidjeti dio 5.1).
The duration of treatment should not exceed that evaluated during clinical trial (mean 7 days) (see sections 4.2, 4.3 and 5.2).
Liječenje ne smije trajati dulje nego što je ispitivano u kliničkim studijama (prosječno 7 dana) (vidjeti dio 4.2, 4.3 i 5.2).
If follow up treatment with a Vitamin K antagonist is required, treatment with fondaparinux should be continued until the target INR value has been reached.
Ako je potrebno daljnje liječenje antagonistom vitamina K, treba nastaviti liječenje fondaparinuksom do postizanja ciljne vrijednosti INR.
• Store below 25°C.
• Čuvati na temperaturi ispod 25°C.
This dose may be reduced to 7.5 mg once a day if you have moderate kidney disease.
Ova doza može biti smanjena na 7,5 mg jednom na dan ukoliko imate umjereno oštećenje bubrega.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja farmakološke sigurnosti, toksičnosti ponovljenih doza i genotoksičnosti.
A total of 2,184 patients were treated; for both groups, patients were treated for at least 5 days and up to 22 days (mean 7 days).
Ukupno je liječeno 2184 bolesnika; u obje skupine liječenje je trajalo najmanje 5, a najviše 22 dana (prosječno 7 dana).
A pilot dose-finding and pharmacokinetic study of fondaparinux in children with deep vein thrombosis
Pilot studija određivanja doze fondaparinuksa i farmakokinetike u djece s dubokom venskom trombozom
Only fondaparinux can be used to calibrate the anti-Xa assay (the international standards of heparin or LMWH are not appropriate for this use).
Za kalibriranje anti-Xa testa može se koristiti samo fondaparinuks (međunarodni standardi heparina i niskomolekularnog heparina nisu primjereni za tu svrhu).
It is available in packs of 2, 7, 10 and 20 pre-filled syringes (not all pack sizes may be marketed).
Dostupna je u pakiranju s 2, 7, 10 i 20 napunjenih štrcaljki (na tržištu se ne moraju nalaziti sve veličine pakiranja).
The subcutaneous injection is administered in the same way as with a classical syringe.
Supkutana injekcija se daje na isti način kao i s klasičnom štrcaljkom.
• It is normal to see a small air bubble in this syringe.
• Prisutnost malog mjehurića zraka u štrcaljki je normalna.
Plasma concentrations of half the mean Cmax values are reached 25 minutes post-dosing.
Koncentracije u plazmi u vrijednosti pola prosječnog Cmax postižu se 25 minuta po primjeni doze.
In these patients the use of prolonged prophylaxis with fondaparinux should be considered for up to an additional 24 days (see section 5.1).
U tih bolesnika treba razmotriti produljenu profilaktičku primjenu fondaparinuksa sve do 24 dodatna dana (vidjeti dio 5.1).
Experience shows that in patients undergoing hip fracture surgery, the risk of VTE continues beyond 9 days after surgery.
Iskustvo pokazuje da u bolesnika nakon operacije slomljenog kuka rizik od VTE postoji i dulje od 9 dana nakon operacije.
Medical patients who are at high risk for thromboembolic complications based on an individual risk assessment
Nekirurški bolesnici koji su pod visokim rizikom nastanka tromboembolijskih komplikacija na temelju individualne procjene rizika
Picture B1
Slika B1
The efficacy and safety of fondaparinux have not been formally studied in patients with HIT type II.
Djelotvornost i sigurnost primjene fondaparinuksa nisu formalno ispitivane u bolesnika s HIT-om tipa II.
There are limited clinical data available from patients with creatinine clearance less than 30 ml/min.
Ograničeni su klinički podaci za bolesnike s klirensom kreatinina manjim od 30 ml/min.
The study population was 64% female, with a median age of 58 years, 4.4% had a creatinine clearance <50ml/min.
U ispitivanju je sudjelovalo 64% žena, s prosjekom godina 58, a 4,4% ispitanika je imalo klirens kreatinina <50 ml/min.
Rare: non-protein-nitrogen (Npn) 2 increased
Poremećaji metabolizma i prehrane Rijetko: povišene razine neproteinskog dušika (Npn)2
Clean the injection area with an alcohol wipe.
Dezinficirajte područje injiciranja vaticom i alkoholom.
As for other anticoagulants, fondaparinux should be used with caution in patients who have undergone recent surgery (<3 days) and only once surgical haemostasis has been established.
Kao i ostale antikoagulanse, fondaparinuks treba primjenjivati uz oprez u bolesnika koji su nedavno podvrgnuti operativnom zahvatu (< 3 dana) i to tek nakon što je uspostavljena kirurška hemostaza.
• increase in bilirubin (a substance produced by the liver) in the blood
• povišeni bilirubin (tvar koju proizvodi jetra) u krvi
The mean age of the patients was 67 years, and approximately 60% were at least 65 years old.
Prosječna dob bolesnika iznosila je 67 godina, a otprilike ih je 60% bilo staro najmanje 65 godina.
Arixtra does not contain any animal products.
Arixtra ne sadržava sastojke životinjskog podrijetla.
The mean treatment duration was 5.5 days in the fondaparinux group and 5.2 days in the enoxaparin group.
Prosječno trajanje liječenja iznosilo je 5,5 dana u skupini liječenoj fondaparinuksom i 5,2 dana u skupini liječenoj enoksaparinom.
After subcutaneous dosing, fondaparinux is completely and rapidly absorbed (absolute bioavailability 100%).
Nakon supkutane primjene fondaparinuks se potpuno i vrlo brzo apsorbira (apsolutna bioraspoloživost 100%).
Four (0.3%) non-randomised patients experienced thrombus in the diagnostic catheter during coronary angiography.
Četiri su nerandomizirana bolesnika (0,3%) doživjela trombozu dijagnostičkog katetera tijekom koronarografije.
Fondaparinux is excreted in rat milk but it is not known whether fondaparinux is excreted in human milk.
Fondaparinuks se izlučuje u mlijeko štakora, ali nije poznato izlučuje li se u majčino mlijeko.
The safety and efficacy of 1.5 mg has not been studied.
Sigurnost i djelotvornost primjene doze od 1,5 mg nije bila proučavana.
Fondaparinux doses above the recommended regimen may lead to an increased risk of bleeding.
Fondaparinuks u dozama višim od preporučene sheme doziranja može povećati rizik od krvarenja.
Picture B2
Slika B2
Arixtra is used to treat adults with a blood clot in the blood vessels of their legs (deep vein thrombosis) and/or lungs (pulmonary embolism).
Arixtra se koristi za liječenje odraslih bolesnika s ugrušcima krvi u krvnim žilama nogu (duboka venska tromboza) i/ili pluća (plućna embolija).
• if you are allergic to fondaparinux sodium or to any of the other ingredients of this medicine
• ako ste alergični na fondaparinuksnatrij ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
Associated terminal half-life values were 29 h in moderate and 72 h in patients with severe renal impairment.
Pripadajuće terminalne vrijednosti poluživota iznosile su 29 sati kod umjerenog, te 72 sata kod teškog oštećenja bubrega.
Fondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa).
Fondaparinuks je sintetski i selektivni inhibitor aktiviranog faktora X (Xa).
Treatment of ST segment elevation myocardial infarction (STEMI) in adults who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
Liječenje infarkta miokarda s elevacijom ST-segmenta (STEMI) u odraslih bolesnika koji se liječe tromboliticima ili u onih koji u početku neće primati nijedan drugi oblik reperfuzijskog liječenja.
Both treatment groups received Vitamin K antagonist therapy usually initiated within 72 hours after the first study drug administration and continued for 90 ± 7 days, with regular dose adjustments to achieve an INR of 2-3.
Obje skupine primale su antagonist vitamina K, koji se počeo davati obično unutar 72 sata od prve primjene ispitivanog lijeka, a davao se tijekom 90 ± 7 dana, uz redovitu prilagodbu doze kako bi se postigla vrijednost INR od 2-3.
• allergic reaction (including itching, swelling, rash)
• alergijske reakcije (uključujući svrbež, oticanje, osip)
Fondaparinux should not be prescribed to pregnant women unless clearly necessary.
Fondaparinuks se ne smije propisivati trudnicama osim kada je to nedvojbeno neophodno.
All enrolled patients received fondaparinux 2.5 mg subcutaneously, once daily for up to 8 days, or until hospital discharge.
Svi su uključeni bolesnici primili 2,5 mg fondaparinuksa supkutano, jednom dnevno kroz 8 dana ili do otpusta iz bolnice.
Fondaparinux is intended for subcutaneous use only.
Fondaparinuks je namijenjen samo za supkutanu primjenu.